Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399

Once-daily aminoglycoside therapy.

D N Gilbert 1
PMCID: PMC245022  PMID: 2039189

Abstract

The once-daily administration of aminoglycosides is an attractive concept. In animal experiments and clinical trials, there is either a reduction in or no influence on the risk of toxicity. Less frequent dosing reduces the contact time between host tissue binding sites and drug. Thanks to the PAE and perhaps other as-yet-unrecognized factors, the fall in the level in serum below the MIC does not appear to impair antibacterial efficacy; in fact, the higher peak level in serum may enhance drug efficacy early in a dosage interval. In neutropenic patients, the in vivo PAE may be lost or small-colony variants with a shorter PAE may be selected unless a concomitant beta-lactam is administered. Because it will be some time before data from clinical trials in the United States are available, because the results from the international trials are encouraging, and because there is potential benefit to patients, it seems reasonable for infectious diseases consultants to cautiously initiate the educational process necessary to implement once-daily aminoglycoside therapy in their institutions.

Full text

PDF
399

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bamonte F., Dionisotti S., Gamba M., Ongini E., Arpini A., Melone G. Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig. Chemotherapy. 1990;36(1):41–50. doi: 10.1159/000238747. [DOI] [PubMed] [Google Scholar]
  2. Bennett W. M., Hartnett M. N., Gilbert D., Houghton D., Porter G. A. Effect of sodium intake on gentamicin nephrotoxicity in the rat. Proc Soc Exp Biol Med. 1976 Apr;151(4):736–738. doi: 10.3181/00379727-151-39296. [DOI] [PubMed] [Google Scholar]
  3. Bennett W. M., Plamp C. E., Gilbert D. N., Parker R. A., Porter G. A. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis. 1979 Oct;140(4):576–580. doi: 10.1093/infdis/140.4.576. [DOI] [PubMed] [Google Scholar]
  4. Bennett W. M., Wood C. A., Houghton D. C., Gilbert D. N. Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis. 1986 Nov;8(5):292–296. doi: 10.1016/s0272-6386(86)80100-7. [DOI] [PubMed] [Google Scholar]
  5. Blaser J., Stone B. B., Zinner S. H. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother. 1985 Mar;27(3):343–349. doi: 10.1128/aac.27.3.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brummett R. E., Fox K. E. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989 Jun;33(6):797–800. doi: 10.1128/aac.33.6.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bundtzen R. W., Gerber A. U., Cohn D. L., Craig W. A. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 1981 Jan-Feb;3(1):28–37. doi: 10.1093/clinids/3.1.28. [DOI] [PubMed] [Google Scholar]
  8. Bustamante C. I., Drusano G. L., Tatem B. A., Standiford H. C. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Nov;26(5):678–682. doi: 10.1128/aac.26.5.678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Craig W. A., Vogelman B. The postantibiotic effect. Ann Intern Med. 1987 Jun;106(6):900–902. doi: 10.7326/0003-4819-106-6-900. [DOI] [PubMed] [Google Scholar]
  10. Davis B. D. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev. 1987 Sep;51(3):341–350. doi: 10.1128/mr.51.3.341-350.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Davis R. R., Brummett R. E., Bendrick T. W., Himes D. L. Dissociation of maximum concentration of kanamycin in plasma and perilymph from ototoxic effect. J Antimicrob Chemother. 1984 Sep;14(3):291–302. doi: 10.1093/jac/14.3.291. [DOI] [PubMed] [Google Scholar]
  12. De Broe M. E., Giuliano R. A., Verpooten G. A. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med. 1986 Jun 30;80(6B):115–118. doi: 10.1016/0002-9343(86)90488-2. [DOI] [PubMed] [Google Scholar]
  13. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Elliott W. C., Parker R. A., Houghton D. C., Gilbert D. N., Porter G. A., DeFehr J., Bennett W. M. Effect of sodium bicarbonate and ammonium chloride ingestion in experimental gentamicin nephrotoxicity in rats. Res Commun Chem Pathol Pharmacol. 1980 Jun;28(3):483–495. [PubMed] [Google Scholar]
  15. English J., Gilbert D. N., Kohlhepp S., Kohnen P. W., Mayor G., Houghton D. C., Bennett W. M. Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother. 1985 Jun;27(6):897–902. doi: 10.1128/aac.27.6.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fan S. T., Lau W. Y., Teoh-Chan C. H., Lau K. F., Mauracher E. H. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother. 1988 Jul;22(1):69–74. doi: 10.1093/jac/22.1.69. [DOI] [PubMed] [Google Scholar]
  17. Feld R., Rachlis A., Tuffnell P. G., Duncan I., Moran L., Pinfold P., DeBoer G. Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Arch Intern Med. 1984 May;144(5):1005–1010. [PubMed] [Google Scholar]
  18. Feld R., Valdivieso M., Bodey G. P., Rodriguez V. A comparative trial of sisomicin therapy by intermittent versus continuous infusion. Am J Med Sci. 1977 Sep-Oct;274(2):179–188. doi: 10.1097/00000441-197709000-00010. [DOI] [PubMed] [Google Scholar]
  19. Frame P. T., Phair J. P., Watanakunakorn C., Bannister T. W. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis. 1977 Jun;135(6):952–956. doi: 10.1093/infdis/135.6.952. [DOI] [PubMed] [Google Scholar]
  20. Gerber A. U., Craig W. A., Brugger H. P., Feller C., Vastola A. P., Brandel J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis. 1983 May;147(5):910–917. doi: 10.1093/infdis/147.5.910. [DOI] [PubMed] [Google Scholar]
  21. Gerber A. U., Feller-Segessenmann C. In-vivo assessment of in-vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):201–206. doi: 10.1093/jac/15.suppl_a.201. [DOI] [PubMed] [Google Scholar]
  22. Gerber A. U., Wiprächtiger P., Stettler-Spichiger U., Lebek G. Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro. J Infect Dis. 1982 Apr;145(4):554–560. doi: 10.1093/infdis/145.4.554. [DOI] [PubMed] [Google Scholar]
  23. Gilbert D. N., Bennett W. M. Use of antimicrobial agents in renal failure. Infect Dis Clin North Am. 1989 Sep;3(3):517–531. [PubMed] [Google Scholar]
  24. Gilbert D. N., Wood C. A., Kohlhepp S. J., Kohnen P. W., Houghton D. C., Finkbeiner H. C., Lindsley J., Bennett W. M. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis. 1989 May;159(5):945–953. doi: 10.1093/infdis/159.5.945. [DOI] [PubMed] [Google Scholar]
  25. Giuliano R. A., Verpooten G. A., De Broe M. E. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis. 1986 Nov;8(5):297–303. doi: 10.1016/s0272-6386(86)80101-9. [DOI] [PubMed] [Google Scholar]
  26. Herscovici L., Grise G., Thauvin C., Lemeland J. F., Fillastre J. P. Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scand J Infect Dis. 1988;20(2):205–212. doi: 10.3109/00365548809032439. [DOI] [PubMed] [Google Scholar]
  27. Hollender L. F., Bahnini J., De Manzini N., Lau W. Y., Fan S. T., Hermansyur K., Benny P., Husni A. N., Sutjipto, Lorber R. R. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother. 1989 May;23(5):773–783. doi: 10.1093/jac/23.5.773. [DOI] [PubMed] [Google Scholar]
  28. John J. F., Jr What price success? The continuing saga of the toxic:therapeutic ratio in the use of aminoglycoside antibiotics. J Infect Dis. 1988 Jul;158(1):1–6. doi: 10.1093/infdis/158.1.1. [DOI] [PubMed] [Google Scholar]
  29. Kaloyanides G. J. Renal pharmacology of aminoglycoside antibiotics. Contrib Nephrol. 1984;42:148–167. doi: 10.1159/000409975. [DOI] [PubMed] [Google Scholar]
  30. Kapusnik J. E., Hackbarth C. J., Chambers H. F., Carpenter T., Sande M. A. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis. 1988 Jul;158(1):7–12. doi: 10.1093/infdis/158.1.7. [DOI] [PubMed] [Google Scholar]
  31. Kunin C. M. Dosage schedules of antimicrobial agents: a historical review. Rev Infect Dis. 1981 Jan-Feb;3(1):4–11. doi: 10.1093/clinids/3.1.4. [DOI] [PubMed] [Google Scholar]
  32. MacArthur R. D., Lolans V., Zar F. A., Jackson G. G. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis. 1984 Nov;150(5):778–779. doi: 10.1093/infdis/150.5.778. [DOI] [PubMed] [Google Scholar]
  33. Maller R., Isaksson B., Nilsson L., Sörén L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother. 1988 Jul;22(1):75–79. doi: 10.1093/jac/22.1.75. [DOI] [PubMed] [Google Scholar]
  34. Mattie H., Craig W. A., Pechère J. C. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989 Sep;24(3):281–293. doi: 10.1093/jac/24.3.281. [DOI] [PubMed] [Google Scholar]
  35. Matzke G. R., Lucarotti R. L., Shapiro H. S. Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol. 1983 Jan-Feb;3(1):11–17. doi: 10.1159/000166680. [DOI] [PubMed] [Google Scholar]
  36. Miller M. H., Feinstein S. A., Chow R. T. Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1987 Jan;31(1):108–110. doi: 10.1128/aac.31.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  38. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  39. Mordenti J. J., Quintiliani R., Nightingale C. H. Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):313–321. doi: 10.1093/jac/15.suppl_a.313. [DOI] [PubMed] [Google Scholar]
  40. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Nordström L., Ringberg H., Cronberg S., Tjernström O., Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother. 1990 Jan;25(1):159–173. doi: 10.1093/jac/25.1.159. [DOI] [PubMed] [Google Scholar]
  42. Olier B., Viotte G., Morin J. P., Fillastre J. P. Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach. Chemotherapy. 1983;29(6):385–394. doi: 10.1159/000238225. [DOI] [PubMed] [Google Scholar]
  43. Paradelis A. G., Triantaphyllidis C. J., Mironidou M., Crassaris L. G., Karachalios D. N., Giala M. M. Interaction of aminoglycoside antibiotics and calcium channel blockers at the neuromuscular junctions. Methods Find Exp Clin Pharmacol. 1988 Nov;10(11):687–690. [PubMed] [Google Scholar]
  44. Pierre C., Blanchet F., Seta N., Chaigne P., Labarre C., Sterkers O., Amiel C., Carbon C. Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers. Clin Pharmacol Ther. 1988 Oct;44(4):458–466. doi: 10.1038/clpt.1988.180. [DOI] [PubMed] [Google Scholar]
  45. Powell S. H., Thompson W. L., Luthe M. A., Stern R. C., Grossniklaus D. A., Bloxham D. D., Groden D. L., Jacobs M. R., DiScenna A. O., Cash H. A. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis. 1983 May;147(5):918–932. doi: 10.1093/infdis/147.5.918. [DOI] [PubMed] [Google Scholar]
  46. Proctor L., Petty B., Thakor R., Lietman P., Glackin R., Shimizu H. A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin. Laryngoscope. 1987 Dec;97(12):1443–1449. doi: 10.1288/00005537-198712000-00012. [DOI] [PubMed] [Google Scholar]
  47. Quarum M. L., Houghton D. C., Gilbert D. N., McCarron D. A., Bennett W. M. Increasing dietary calcium moderates experimental gentamicin nephrotoxicity. J Lab Clin Med. 1984 Jan;103(1):104–114. [PubMed] [Google Scholar]
  48. Reiner N. E., Bloxham D. D., Thompson W. L. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother. 1978 May;4 (Suppl A):85–101. doi: 10.1093/jac/4.suppl_a.85. [DOI] [PubMed] [Google Scholar]
  49. Roosendaal R., Bakker-Woudenberg I. A., van den Berghe-van Raffe M., Vink-van den Berg J. C., Michel B. M. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):878–887. doi: 10.1007/BF01963774. [DOI] [PubMed] [Google Scholar]
  50. Rotheram E. B., Jr Clinical response and peak concentrations of aminoglycosides. J Infect Dis. 1988 Feb;157(2):395–396. doi: 10.1093/infdis/157.2.395. [DOI] [PubMed] [Google Scholar]
  51. Sabra R., Branch R. A. Role of sodium in protection by extended-spectrum penicillins against tobramycin-induced nephrotoxicity. Antimicrob Agents Chemother. 1990 Jun;34(6):1020–1025. doi: 10.1128/aac.34.6.1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Sturm A. W. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989 May;159(5):931–937. doi: 10.1093/infdis/159.5.931. [DOI] [PubMed] [Google Scholar]
  53. Teixeira R. B., Kelley J., Alpert H., Pardo V., Vaamonde C. A. Complete protection from gentamicin-induced acute renal failure in the diabetes mellitus rat. Kidney Int. 1982 Apr;21(4):600–612. doi: 10.1038/ki.1982.67. [DOI] [PubMed] [Google Scholar]
  54. Tran Ba Huy P., Bernard P., Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest. 1986 May;77(5):1492–1500. doi: 10.1172/JCI112463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Tran Ba Huy P., Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol. 1988 May-Jun;105(5-6):511–515. doi: 10.3109/00016488809119511. [DOI] [PubMed] [Google Scholar]
  56. Verpooten G. A., Giuliano R. A., Verbist L., Eestermans G., De Broe M. E. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989 Jan;45(1):22–27. doi: 10.1038/clpt.1989.4. [DOI] [PubMed] [Google Scholar]
  57. Vogelman B. S., Craig W. A. Postantibiotic effects. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):37–46. doi: 10.1093/jac/15.suppl_a.37. [DOI] [PubMed] [Google Scholar]
  58. Vogelman B., Craig W. A. Kinetics of antimicrobial activity. J Pediatr. 1986 May;108(5 Pt 2):835–840. doi: 10.1016/s0022-3476(86)80754-5. [DOI] [PubMed] [Google Scholar]
  59. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W. A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988 Oct;158(4):831–847. doi: 10.1093/infdis/158.4.831. [DOI] [PubMed] [Google Scholar]
  60. Vogelman B., Gudmundsson S., Turnidge J., Leggett J., Craig W. A. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988 Feb;157(2):287–298. doi: 10.1093/infdis/157.2.287. [DOI] [PubMed] [Google Scholar]
  61. Wood C. A., Kohlhepp S. J., Kohnen P. W., Houghton D. C., Gilbert D. N. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1986 Jul;30(1):20–24. doi: 10.1128/aac.30.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Wood C. A., Norton D. R., Kohlhepp S. J., Kohnen P. W., Porter G. A., Houghton D. C., Brummett R. E., Bennett W. M., Gilbert D. N. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis. 1988 Jul;158(1):13–22. doi: 10.1093/infdis/158.1.13. [DOI] [PubMed] [Google Scholar]
  63. Yourassowsky E., Van der Linden M. P., Crokaert F. One shot of high-dose amikacin: a working hypothesis. Chemotherapy. 1990;36(1):1–7. doi: 10.1159/000238741. [DOI] [PubMed] [Google Scholar]
  64. ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES